TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00690196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih
Description: Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
Study: NCT02324764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidesheath Slender
Description: testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard 6- French radial sheath
Study: NCT03229434

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mountain hiking
Description: Compare arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mountain hiking
Description: Compare arm description
Study: NCT01278108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0778
Description: single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution or capsule (matching corresponding study medication)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0778
Description: multiple dose, capsule, 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, capsule, 7 days
Study: NCT02141958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo will be used to keep the study double-blind.
Study: NCT03101124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 25 mg/ml for wound surface moistening
Description: Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 5 mg/ml as bolus in wound cavity
Description: 200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injectable Solution
Description: 1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
Study: NCT03780270

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnish
Description: Fluor Protector S (Ivoclar, 7'700 ppm F-)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: Fluor Protector S (Ivoclar, 7'700 ppm F-)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: P11-4 (monomeric peptide) - for professional use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: P11-4 (monomeric peptide) - for professional use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Protect
Description: Tooth gel (containing P11-4 assembled to a fibrillary matrix) - for home use (OTC)
Study: NCT02468934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study: NCT02397265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-hormonal closed loop pump
Description: Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard opened loop pump
Description: Using a standard opened loop pump

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Insulin closed loop
Description: Using a closed loop
Study: NCT04922190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Coaching
Description: Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
Study: NCT00997256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))
Description: 3 x 2 tablets / day over 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: film-coated sugar-pill
Description: 3 x 2 tablets / day over 3 days
Study: NCT02884557

Intervention type: OTHER
Group type: OTHER
Intervention: collection of gut biopsies collection of blood samples
Description: Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.

Intervention type: OTHER
Group type: OTHER
Intervention: collection of gut biopsies collection of blood samples
Description: Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
Study: NCT00850304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosar
Description: Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
Study: NCT02535130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amikacine nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amikacine nebulization
Study: NCT02720744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT218

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00201461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARFlex septal closure system
Description: transcatheter placement of STARFlex device to close a patent foramen ovale

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical therapy
Description: aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
Study: NCT05983003

Intervention type: PROCEDURE
Intervention: endoscopic sinus surgery
Description: Open the sinus ostium, improve anatomical issues and remove the diseased tissue.

Intervention type: PROCEDURE
Intervention: endoscopic sinus surgery
Description: Open the sinus ostium, improve anatomical issues and remove the diseased tissue.
Study: NCT03140332

Intervention type: OTHER
Group type: OTHER
Intervention: Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib
Description: To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
Study: NCT00348790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Study: NCT01775358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-5281 0.015 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-5281 0.05 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-5281 0.15 mg/kg
Study: NCT00506753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI/CBT
Description: Motivational Interviewing followed by Cognitive Behavior Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT/SU
Description: Relaxation Training followed by Treatment as Usual
Study: NCT01775358

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.015 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.05mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.15mg/kg
Study: NCT03375671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketalar
Description: single administration of 5 mg/kg, IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: single administration of 5 mg, IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: single administration of 5 mg, IM
Study: NCT01967706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mTHS
Description: Single use of Tobacco Heating System 2.2 Menthol (mTHS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mTHS
Description: Single use of Tobacco Heating System 2.2 Menthol (mTHS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mTHS
Description: Single use of Tobacco Heating System 2.2 Menthol (mTHS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mTHS
Description: Single use of Tobacco Heating System 2.2 Menthol (mTHS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mCC
Description: Single use of subject's own menthol cigarette (mCC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mCC
Description: Single use of subject's own menthol cigarette (mCC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NRT
Description: Single administration of 2 mg gum (Nicorette® 2mg)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NRT
Description: Single administration of 2 mg gum (Nicorette® 2mg)
Study: NCT04305249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-017
Description: Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-017+Nivolumab
Description: With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be specified dose on specified days.
Study: NCT02089334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-0201
Description: RX-0201 will be administered in a dose up to 250mg/m\^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles.
Study: NCT04679636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback
Description: receive biofeedback training for heart rate variability for eight weeks
Study: NCT04638881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.
Study: NCT03495648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking group led by a community organizer
Description: Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking group led by a community organizer
Description: Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
Study: NCT00617461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 1200mg/day
Description: 1200mg/day gabapentin enacarbil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 3600mg/day
Description: 3600mg/day gabapentin enacarbil
Study: NCT00944970

Intervention type: DRUG
Group type: OTHER
Intervention: binodenoson
Description: 30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo

Intervention type: DRUG
Group type: OTHER
Intervention: binodenoson
Description: 30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)

Intervention type: DRUG
Group type: OTHER
Intervention: adenosine
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)

Intervention type: DRUG
Group type: OTHER
Intervention: adenosine
Description: 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
Study: NCT02102165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metastatic lesion biopsy
Description: a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
Study: NCT03879213

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active breakfast
Description: freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control breakfast
Description: Control drink + buttermilk biscuit sandwich
Study: NCT00910182

Intervention type: PROCEDURE
Intervention: splenorrhaphy
Description: surgical treatment of splenic injuries after blunt abdominal trauma.
Study: NCT04428671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study: NCT04184037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation delivered via a mobile app
Description: This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation delivered via a mobile app
Description: This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided.
Study: NCT02686216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 THK-5351
Description: Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
Study: NCT02901899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04638881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo. Bolus and infusion administered similarly under general anesthesia.
Study: NCT04531254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearing a face mask at all times
Description: Children in this group will be asked to wear a face mask in the classroom and common areas during the simulation
Study: NCT06209398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell )
Description: Used for EV71 virus susceptible individuals aged 6 months to 5 years. Each bottle (bottle) contains 0.5ml of neutralizing antibody with a potency of no less than 3.0EU for the inactivated 71 type intestinal disease vaccine. Intramuscular injection into the deltoid muscle of the upper arm. The immunization program consists of 2 doses with 1-month interval.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell )
Description: Used for EV71 virus susceptible individuals aged 6 months to 5 years. Each bottle (bottle) contains 0.5ml of neutralizing antibody with a potency of no less than 3.0EU for the inactivated 71 type intestinal disease vaccine. Intramuscular injection into the deltoid muscle of the upper arm. The immunization program consists of 2 doses with 1-month interval.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B Vaccine
Description: Each vaccine bottle (tube) is 0.5ml, containing 10ug of HBsAg and inject into the upper deltoid muscle. The immunization program consists of three doses, administered at 0, 1, and 6 months respectively. Newborns are given the first dose within 24 hours after birth, with one dose of vaccine administered each time.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis B Vaccine
Description: Each vaccine bottle (tube) is 0.5ml, containing 10ug of HBsAg and inject into the upper deltoid muscle. The immunization program consists of three doses, administered at 0, 1, and 6 months respectively. Newborns are given the first dose within 24 hours after birth, with one dose of vaccine administered each time.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A meningococcal polysaccharide vaccine
Description: This product is made by lyophilizing the purified polysaccharide antigen obtained from Group A meningococcus liquid culture. The vaccination targets children aged 6 months to 15 years old, and the initial immunization age starts from 6 months old. Infants and young children aged 6 to 12 months old are vaccinated with 2 doses of 30 micrograms, with an interval of 3 months. Subcutaneously inject 0.5ml into the lateral deltoid muscle of the upper arm at a dose of 30 μg of polysaccharide antigen (0.5ml).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A meningococcal polysaccharide vaccine
Description: This product is made by lyophilizing the purified polysaccharide antigen obtained from Group A meningococcus liquid culture. The vaccination targets children aged 6 months to 15 years old, and the initial immunization age starts from 6 months old. Infants and young children aged 6 to 12 months old are vaccinated with 2 doses of 30 micrograms, with an interval of 3 months. Subcutaneously inject 0.5ml into the lateral deltoid muscle of the upper arm at a dose of 30 μg of polysaccharide antigen (0.5ml).
Study: NCT02133794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomosynthesis